Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032, the company's oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is designed to reduce serotonin production in patients with metastatic carcinoid tumors. Elevated levels of serotonin contribute to the gastrointestinal and possibly other symptoms experienced by these patients.

In addition to LX1032, Lexicon has three other drug candidates progressing through various stages of clinical development, including LX1031 for irritable bowel syndrome, LX2931 for rheumatoid arthritis, and LX4211 for diabetes. For more information about Lexicon's clinical development programs, please visit www.lexpharma.com.

"This is an important study, designed to evaluate LX1032's effect on the gastrointestinal symptoms experienced by patients with carcinoid syndrome who have become refractory to current treatment options," said Philip M. Brown, M.D., J.D., senior vice president of clinical development at Lexicon. "We are encouraged by the clinical results obtained to date in which LX1032 demonstrated potent reductions in serotonin production in healthy volunteers."

The Phase 2 clinical trial is designed as a four-week, randomi
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015 CytomX, a biotechnology ... today announced that Sean McCarthy , D. Phil., ... Antibody Day in New York ... McCarthy will present an overview of CytomX,s Probody pipeline, ... conjugate programs. About CytomX Therapeutics CytomX ...
(Date:5/5/2015)... May 5, 2015  Indianapolis-based medical device manufacturer ... innovative line of products including the BrainPath® and ... accessing deep-seated brain abnormalities and then removing affected ... at more than 50 institutions throughout ... also been included in 12 abstracts, three peer-reviewed ...
(Date:5/4/2015)... JSS Medical Research Inc., a Montreal based ... of Max Neeman International (MNI), with head office in ... Ahmedabad, Bangalore , Chennai ... regional office is located North Carolina, USA . ... equity investment transaction into JSS with Capital Croissance PME (CCPME), a ...
(Date:5/4/2015)... 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), a FACIT ... of Dr. Roger J Garceau, to its Board ... in matters including corporate development and clinical strategy, ... significant regulatory expertise as Fluorinov transitions to clinical ... years of pharmaceutical development experience to Fluorinov and ...
Breaking Biology Technology:NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3JSS Medical Canada widens its global presence across Asia/Pacific region 2JSS Medical Canada widens its global presence across Asia/Pacific region 3JSS Medical Canada widens its global presence across Asia/Pacific region 4Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3
... BEIJING, Aug. 14 /PRNewswire-Asia-FirstCall/ -- Lotus ... growing developer and,producer of prescription drugs and licensed national seller ... financial results,for the quarter and six months ended June 30, ... Highlights and Developments:, -- Q2 diluted EPS ...
... HARBIN, China, Aug. 14 /PRNewswire-Asia-FirstCall/ -- ... Company") (Nasdaq: CSKI ), a,leading fully integrated pharmaceutical ... financial results for the second quarter,of 2009. , , ... Total revenues increased 35.5% year-over-year to $32.2 million, ...
... ... for ISP,s Vincience™ Biofunctional Ingredients, Rapidly and Effectively , ... (PRWEB) August 14, 2009 -- ... global supplier of advanced personal care ingredients, announced that they have formed an ...
Cached Biology Technology:Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 2Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 3Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 4Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 5Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 6Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 7Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 8Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 9Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 10Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 11China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 2China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 3China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 4China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 5China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 6China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 7China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 8China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 9China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 10China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 11Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics-Based Computer Modeling of Skin Biology 2Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics-Based Computer Modeling of Skin Biology 3Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics-Based Computer Modeling of Skin Biology 4
(Date:4/13/2015)... , April 13, 2015  higi, a leading cloud-based ... to more fully engage with their communities around health ... privacy protected and secure API.  ... the most accessible, affordable, and convenient vehicle to receive ... The API will allow higi,s ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... , April 2, 2015 At its 2015 ... Lake City , the American College of Medical ... new directors to its Board.  Members of the ACMG ... and for forming and advancing its policies and programs. ... profession. "It,s an eventful time in medical ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... University, in London, Canada, have developed a CT (Computed Tomography) ... Battista, Chair of the Department of Medical Biophysics at the ... the London Regional Cancer Program at London Health Sciences Centre ... interactive way to teach CT imaging techniques to a wide ...
... Research Institute (OHRI) and the University of Ottawa (uOttawa) has ... (CIHR) and $75,000 from the Stem Cell Network to lead ... cell therapy for septic shock. This deadly condition occurs when ... system, resulting in severe organ damage and death in 30 ...
... Epigenetics is the new hip science. Time Magazine,s front cover ... explains why. Its more explicit subtitle provided the hook - ,The ... change your genes - and those of your kids,. Who ... ways in which the genetic code in our DNA is regulated ...
Cached Biology News:Mini-CT scanner developed as a teaching tool 2Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock 2Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock 3Epigenetics and epidemiology -- hip, hype and science 2Epigenetics and epidemiology -- hip, hype and science 3
anti-Lactate Dehydrogenase...
6-keto Prostaglandin F1α EIA Antiserum 6-keto-PGF1alpha EIAs prostaglandins antisera enzyme immunoassays reagents 6-keto-PGF1.alpha....
... developed for use with immunohistochemical (IHC) ... background staining due to endogenous peroxidase. ... with hydrogen peroxide. This reagent ... additional novel components to further quench ...
Phospho-Btk (Tyr223) Antibody...
Biology Products: